New Incyte, Merck skin cancer immunotherapy study results disclosed, and they look promising – STAT
|
New Incyte, Merck skin cancer immunotherapy study results disclosed, and they look promising
STAT pdated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte's epacadostat combined with Merck's Keytruda to treat patients with metastatic melanoma. The new data, culled from the study Incyte calls ECHO-202, look good … |
